Galecto trading resumes
PremiumThe FlyGalecto trading resumes
11d ago
Ten option delistings on March 24th
Premium
The Fly
Ten option delistings on March 24th
12d ago
Galecto, Inc.’s Strategic Shift to Oncology and Liver Diseases: Navigating Risks and Opportunities
Premium
Company Announcements
Galecto, Inc.’s Strategic Shift to Oncology and Liver Diseases: Navigating Risks and Opportunities
5M ago
Galecto announces the appointment of Wechsler to its Board of Directors
PremiumThe FlyGalecto announces the appointment of Wechsler to its Board of Directors
6M ago
Arcadium confirms Rio approach, Apollo funds to acquire Barnes: Morning Buzz
Premium
The Fly
Arcadium confirms Rio approach, Apollo funds to acquire Barnes: Morning Buzz
6M ago
Galecto completes strategic review, will focus on oncology, liver disease
Premium
The Fly
Galecto completes strategic review, will focus on oncology, liver disease
6M ago
Galecto announces 1-for-25 reverse stock split
PremiumThe FlyGalecto announces 1-for-25 reverse stock split
7M ago
Galecto price target lowered to $9 from $10 at Oppenheimer
Premium
The Fly
Galecto price target lowered to $9 from $10 at Oppenheimer
10M ago
Galecto enrolls first patient in GB1211 trial
Premium
The Fly
Galecto enrolls first patient in GB1211 trial
11M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100